Page last updated: 2024-12-08

n-acetylcolchinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-acetylcolchinol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID242436
CHEMBL ID486504
SCHEMBL ID5441108
MeSH IDM0068875

Synonyms (25)

Synonym
mls002667429 ,
38838-26-5
nsc-51045
n-acetylcolchicinol
rso 23274
nci 1894
nsc51045
colchinol, n-acetyl-
skf 2861
n-acetylcolchinol
n-acetyl colchinol
MLS001243434
smr000841585
(-)-n-acetylcolchinol
desphosphoryl zd-6126
CHEMBL486504
NCGC00247400-01
HMS2216F24
us8hxq60im ,
WJJZQSCOTJYYSP-INIZCTEOSA-N
n-acetyl-colchinol
SCHEMBL5441108
acetamide, n-(6,7-dihydro-3-hydroxy-9,10,11-trimethoxy-5h-dibenzo(a,c)cyclohepten-5-yl)-, (s)-
DTXSID00959625
n-(3-hydroxy-9,10,11-trimethoxy-6,7-dihydro-5h-dibenzo[a,c][7]annulen-5-yl)ethanimidic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency1.92540.004110.890331.5287AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency0.19730.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency6.22050.00527.809829.0929AID588855; AID720534; AID720536; AID720537
67.9K proteinVaccinia virusPotency0.89130.00018.4406100.0000AID720580
IDH1Homo sapiens (human)Potency0.03260.005210.865235.4813AID686970
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency5.17350.00419.984825.9290AID504444
gemininHomo sapiens (human)Potency0.19700.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PAX8Homo sapiens (human)AC500.37000.04885.435469.1700AID687027
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID404617Antiproliferative activity against human HT29 cells after 72 hrs2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
New C5-alkylated indolobenzazepinones acting as inhibitors of tubulin polymerization: cytotoxic and antitumor activities.
AID404609Inhibition of sheep brain tubulin polymerization2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
New C5-alkylated indolobenzazepinones acting as inhibitors of tubulin polymerization: cytotoxic and antitumor activities.
AID404611Antiproliferative activity against human A549 cells after 72 hrs2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
New C5-alkylated indolobenzazepinones acting as inhibitors of tubulin polymerization: cytotoxic and antitumor activities.
AID404608Cytotoxicity against human KB cells after 72 hrs2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
New C5-alkylated indolobenzazepinones acting as inhibitors of tubulin polymerization: cytotoxic and antitumor activities.
AID404613Antiproliferative activity against human MDA-MB-231 cells after 72 hrs2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
New C5-alkylated indolobenzazepinones acting as inhibitors of tubulin polymerization: cytotoxic and antitumor activities.
AID1673996Antiproliferative activity against human DU145 cells incubated for 72 hrs by WST assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Colchicine Alkaloids and Synthetic Analogues: Current Progress and Perspectives.
AID1673997Antiproliferative activity against human PANC1 cells incubated for 72 hrs by WST assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Colchicine Alkaloids and Synthetic Analogues: Current Progress and Perspectives.
AID404612Antiproliferative activity against human MDA-MB-435 cells after 72 hrs2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
New C5-alkylated indolobenzazepinones acting as inhibitors of tubulin polymerization: cytotoxic and antitumor activities.
AID404659Antitumor activity against human U87 tumor transplanted in chick chorio-allantoic membrane assessed as reduction of tumor volume at 100 uM after 4 days2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
New C5-alkylated indolobenzazepinones acting as inhibitors of tubulin polymerization: cytotoxic and antitumor activities.
AID404616Antiproliferative activity against human K562 cells after 72 hrs2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
New C5-alkylated indolobenzazepinones acting as inhibitors of tubulin polymerization: cytotoxic and antitumor activities.
AID404870Antiproliferative activity against human MCF7 cells after 72 hrs2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
New C5-alkylated indolobenzazepinones acting as inhibitors of tubulin polymerization: cytotoxic and antitumor activities.
AID404610Antiproliferative activity against mouse B16F10 cells after 72 hrs2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
New C5-alkylated indolobenzazepinones acting as inhibitors of tubulin polymerization: cytotoxic and antitumor activities.
AID404618Antiproliferative activity against human HCT116 cells after 72 hrs2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
New C5-alkylated indolobenzazepinones acting as inhibitors of tubulin polymerization: cytotoxic and antitumor activities.
AID404615Antiproliferative activity against mouse L1210 cells after 72 hrs2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
New C5-alkylated indolobenzazepinones acting as inhibitors of tubulin polymerization: cytotoxic and antitumor activities.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (13.33)18.7374
1990's0 (0.00)18.2507
2000's7 (46.67)29.6817
2010's4 (26.67)24.3611
2020's2 (13.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.27 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.04 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]